HAP Trading, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.

Quarter-by-quarter ownership
HAP Trading, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$800,380
+7.9%
50,400
-44.8%
0.13%
-1.5%
Q2 2023$741,763
+24725333.3%
91,300
+352.0%
0.13%
Q4 2022$3
-100.0%
20,200
-38.0%
0.00%
-100.0%
Q3 2022$286,000
-34.4%
32,600
-13.3%
0.02%
-9.5%
Q2 2022$436,000
-70.4%
37,600
-30.3%
0.02%
-66.1%
Q1 2022$1,475,000
-31.3%
53,951
-25.9%
0.06%
+6.9%
Q4 2021$2,147,000
+235.5%
72,781
+54.2%
0.06%
+176.2%
Q3 2021$640,000
-29.3%
47,200
-15.6%
0.02%
-25.0%
Q2 2021$905,000
-65.1%
55,900
-56.4%
0.03%
-79.7%
Q1 2021$2,592,000
-23.5%
128,083
+95.1%
0.14%
+40.8%
Q4 2020$3,388,000
+697.2%
65,654
+297.9%
0.10%
+366.7%
Q3 2020$425,000
-65.9%
16,500
-63.7%
0.02%
-69.1%
Q2 2020$1,245,000
+390.2%
45,461
+43.0%
0.07%
+300.0%
Q1 2020$254,000
-39.2%
31,800
-33.2%
0.02%
-26.1%
Q4 2019$418,000
+105.9%
47,600
+60.8%
0.02%
+35.3%
Q3 2019$203,000
+62.4%
29,600
+16.5%
0.02%
+70.0%
Q2 2019$125,000
+12.6%
25,400
-39.8%
0.01%0.0%
Q1 2019$111,000
+484.2%
42,200
+168.8%
0.01%
+900.0%
Q4 2018$19,000
-81.9%
15,700
+12.1%
0.00%
-85.7%
Q3 2018$105,000
+191.7%
14,000
+9.4%
0.01%
+250.0%
Q2 2018$36,00012,8000.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2021
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders